NB-UVB Outperforms Expectations in Biologic Era: JID Review

Narrowband UVB phototherapy beat adalimumab on overall health-related quality of life in one randomized comparison, and a new Journal of Investigative Dermatology perspective says that finding alone should give prescribers pause before defaulting to biologics.

The mini review, published online October 31, 2026, by Samaa Fadel, MS, and Steven R. Feldman, MD, PhD, of Wake Forest, carries a blunt thesis: phototherapy has been "a cornerstone of psoriasis management since before the biologic era" and, "despite being eclipsed by systemic agents, it retains meaningful clinical utility."

That's a countercurrent claim in a market now dominated by TNF, IL-17 and IL-23 inhibitors. The authors build their case on clearance data, mechanistic work, and a landmark home-phototherapy trial.

How did phototherapy get here?

The historical arc matters for interpreting the evidence. Treatment began with broadband UVB (BB-UVB). Then came psoralen plus UVA, or PUVA, which was more potent but carried greater risk. Both have largely given way to NB-UVB, which is more effective than BB-UVB and safer than PUVA.

For context, systemic options once consisted of methotrexate, acitretin, and cyclosporine. Biologics reshaped that landscape. NB-UVB survived it.

What does the evidence show?

The review assembles several lines of support:

• NB-UVB achieves clinically significant clearance rates in plaque psoriasis.
• In the Vascular Inflammation in Psoriasis Trial, a randomized controlled study, patient-reported outcomes favored NB-UVB over adalimumab for overall health-related quality of life improvement (Noe et al., JAAD, 2019).
• NB-UVB works across all skin tones, a persistent concern with some assessment-and-treatment pathways in dermatology.
• Mechanistically, the therapy produces spatially distinct transcriptomic changes within plaques. Work by Boonpethkaew and colleagues (Scientific Reports, 2023) compared edge and center responses within individual lesions. A 2025 study by Arakawa et al. suggests NB-UVB also downregulates HLA-C–mediated antigen presentation on melanocytes, which may contribute to its efficacy.

In plain terms: the light box is doing real immunology, not just cosmetic fading of plaques.

Can patients treat themselves at home?

Yes, and the evidence is strong. The LITE randomized clinical trial, published in JAMA Dermatology in December 2024 by Gelfand and colleagues, found home-based NB-UVB non-inferior to office-based treatment. That matters because office phototherapy typically demands two to three visits per week, a burden that quietly kills adherence for working patients and those far from a phototherapy unit.

Home units change that math entirely. Treatments fit into a patient's evening instead of their commute.

Coverage is also moving. Cigna expanded coverage for home phototherapy, as reported by Dermatology Times on September 12, 2025. The authors describe coverage for home devices as "improving" — a meaningful shift after years in which insurers pushed patients toward in-office care or systemic drugs.

What still stands in the way?

The authors are candid about the obstacles. Three in particular:

• Access barriers, including equipment cost and availability.
• Insurance structure that can make home devices hard to authorize despite improving coverage.
• Limited familiarity among prescribers trained largely in the biologic era.

Their proposed remedies are structural rather than scientific: policy reform, expanded phototherapy coverage, and implementation science to close the gap between trial evidence and everyday prescribing.

Fadel reports no conflicts of interest. Feldman discloses research, speaking and/or consulting support from a long list of manufacturers, including Eli Lilly, AbbVie, Janssen, Pfizer, Amgen, Novartis, UCB, Sanofi, and Regeneron. The commentary used no external funding.

Why this matters now

The perspective lands as biologic prescribing continues to climb and psoriasis guidelines, including the joint AAD–National Psoriasis Foundation phototherapy guidelines of 2019, already endorse light therapy as standard care. The gap isn't in the guidelines. It's in uptake.

For clinicians, the takeaway is straightforward: a treatment that matches a biologic on quality-of-life outcomes, works across skin tones, and now has proven non-inferior home delivery deserves a spot on the treatment ladder — not just a footnote to it. Whether policy reform and payer behavior keep pace with that evidence will determine whether phototherapy's revival extends beyond the literature.